Innoviva (INVA) Stock Forecast & Price Target

Innoviva is supported by a resilient mix of high-margin royalty cash flow, expanding hospital-focused commercial products, and strategic healthcare investments that together reduce dependence on any single asset. Its IST business is showing strong momentum, with U.S. product revenue up 26% y/y to $36.6M and internally marketed products exceeding $180M in LTM revenue as of March 2026, while Breo and Anoro remain durable royalty anchors expected to generate about $1.0B over the next five years. The balance sheet and capital allocation also strengthen the case, as 1Q26 ended with $603.1M in cash, $191.2M in favorable investment value changes, and an active share repurchase program that can compound shareholder returns.

Innoviva is facing fundamental pressure from a weaker royalty business, with $59.8M in revenue down 11% y/y as GSK cited U.S. pricing pressure and softer inhaled respiratory demand, while FactSet consensus for 2026/2027 has already fallen about 6-7%. The company’s pipeline and operating assets add uncertainty, as Zevtera sales remain flattish at roughly $0.4M and expectations were cut from a prior peak of about $72M to $39M in 2033E, alongside clinical and competitive risks for future launches and core products like Relvar/Breo and Anoro. Valuation is further pressured by a roughly 28% decline in Armata shares in 3Q26, implying about $45M in equity losses plus $17M-$20M in warrant value erosion, which reinforces the negative view on capital allocation and asset-backed fair value.